Vaxart (VXRT) Proxy filing summary

Executive summary

• Focus on advancing an oral recombinant vaccine platform, with current programs targeting coronavirus, norovirus, influenza, and HPV.

• Emphasis on the proprietary pill vaccine delivery system, which eliminates the need for refrigeration and needles.

• Forward-looking statements highlight expectations for clinical trial results, regulatory milestones, and strategic partnerships.

Voting matters and shareholder proposals

• Shareholders are urged to vote using the WHITE proxy card in favor of all six incumbent director nominees.

• Communications stress the importance of board continuity and warn against electing nominees lacking relevant biotechnology experience.

Board of directors and corporate governance

• The board is positioned as experienced in building value in biotechnology and overseeing the validation of the oral vaccine platform.